These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 19404210

  • 21. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
    Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T.
    Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K, Gascon P, Krendyukov A, Gattu S, Li Y, Harbeck N.
    Ann Oncol; 2018 Jan 01; 29(1):244-249. PubMed ID: 29091995
    [Abstract] [Full Text] [Related]

  • 23. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C.
    Appl Health Econ Health Policy; 2013 Apr 01; 11(2):129-38. PubMed ID: 23435861
    [Abstract] [Full Text] [Related]

  • 24. [Effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with lung cancer].
    Ohnoshi T, Ueoka H, Kodani T, Kamei H, Kimura I.
    Gan To Kagaku Ryoho; 1990 Apr 01; 17(4 Pt 2):911-8. PubMed ID: 1693062
    [Abstract] [Full Text] [Related]

  • 25. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995 Apr 01; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 26. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK, Chen Q, Zhu YZ, He XH, Wang HQ, Jiang ZF, Chang JH, Liu YP, Wang AL, Luo DY, Zhang Y, Ke XY, Li WL, Zhang WJ, Wang XW, Zhang YP, Wang JM, Liu XQ.
    Anticancer Drugs; 2013 Jul 01; 24(6):641-7. PubMed ID: 23571496
    [Abstract] [Full Text] [Related]

  • 27. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, Dreiling L, Mo M, Malik I.
    Clin Colorectal Cancer; 2010 Apr 01; 9(2):95-101. PubMed ID: 20378503
    [Abstract] [Full Text] [Related]

  • 28. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan 01; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

  • 29. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.
    Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH.
    Invest New Drugs; 2013 Oct 01; 31(5):1300-6. PubMed ID: 23677653
    [Abstract] [Full Text] [Related]

  • 30. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 01; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
    Volovat C, Bondarenko I, Gladkov O, Buchner A, Lammerich A, Müller U, Bias P.
    Support Care Cancer; 2016 Dec 01; 24(12):4913-4920. PubMed ID: 27501966
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Biosimilar filgrastim: from development to record].
    García Alfonso P.
    Farm Hosp; 2010 Mar 01; 34 Suppl 1():19-24. PubMed ID: 20920854
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
    Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB).
    J Thorac Oncol; 2008 Oct 01; 3(10):1159-65. PubMed ID: 18827613
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.
    J Clin Oncol; 2005 Nov 01; 23(31):7974-84. PubMed ID: 16258098
    [Abstract] [Full Text] [Related]

  • 39. Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China.
    Al-Salama ZT, Keam SJ.
    Clin Drug Investig; 2019 Oct 01; 39(10):1009-1018. PubMed ID: 31489570
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.